Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026)

Viatris' (VTRS) quarterly Liabilities and Shareholders Equity came in at $36.8 billion in Q1 2026, down 4.26% year-on-year from $38.5 billion in Q1 2025, and down 0.96% quarter-over-quarter from $37.2 billion in Q4 2025.

Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Viatris' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $36.8 billion for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 4.26% year-over-year to $36.8 billion in Q1 2026; TTM through Mar 2026 was $150.4 billion, a 11.58% decrease from a year earlier, with the FY2025 full-year figure at $37.2 billion, down 10.38% from the prior year.
  • Liabilities and Shareholders Equity declined to $36.8 billion in Q1 2026 per VTRS's latest filing, from $37.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $53.5 billion in Q1 2022 and bottomed at $36.8 billion in Q1 2026.
  • The 5-year median for Liabilities and Shareholders Equity is $47.3 billion (2024), against an average of $45.0 billion.
  • Across the five-year window, Liabilities and Shareholders Equity rose 0.16% in 2023 and declined 18.73% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $50.0 billion in 2022, then decreased by 4.67% to $47.7 billion in 2023, then decreased by 12.97% to $41.5 billion in 2024, then slipped by 10.38% to $37.2 billion in 2025, then slipped by 0.96% to $36.8 billion in 2026.
  • Per Business Quant, the three latest VTRS Liabilities and Shareholders Equity figures stand at $36.8 billion (Q1 2026), $37.2 billion (Q4 2025), and $37.9 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 6.71 Bn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - 25.35 Mn
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 13.22 Bn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn 928.80 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 36.83 Bn
Dec 31, 2025 37.19 Bn
Sep 30, 2025 37.92 Bn
Jun 30, 2025 38.41 Bn
Mar 31, 2025 38.47 Bn
Dec 31, 2024 41.50 Bn
Sep 30, 2024 44.75 Bn
Jun 30, 2024 45.33 Bn
Mar 31, 2024 47.34 Bn
Dec 31, 2023 47.69 Bn
Sep 30, 2023 48.74 Bn
Jun 30, 2023 48.70 Bn
Mar 31, 2023 49.29 Bn
Dec 31, 2022 50.02 Bn
Sep 30, 2022 48.66 Bn
Jun 30, 2022 51.13 Bn
Mar 31, 2022 53.47 Bn
Dec 31, 2021 54.84 Bn
Sep 30, 2021 56.07 Bn
Jun 30, 2021 57.98 Bn